NCTC
DNLI icon

New Covenant Trust Company’s Denali Therapeutics DNLI Stock Holding History

New Covenant Trust Company’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-784
Closed -$16.1K – 175
2024
Q1 		$16.1K Buy
+784
New +$14.7K 0.02% 285

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

New Covenant Trust Company's DNLI Position: Q2 2024 in Review

New Covenant Trust Company sold out of Denali Therapeutics (DNLI) in Q2 2024, closing a stake of 784 shares — an estimated $16.1K sold.

New Covenant Trust Company first reported a position in DNLI in Q1 2024 and held it in 1 quarter. The position peaked at $16.1K in Q1 2024. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2024.

  • New Covenant Trust Company reported no remaining Denali Therapeutics position as of Q2 2024 after selling out during the quarter.
  • New Covenant Trust Company sold 784 Denali Therapeutics shares in Q2 2024, an estimated $16.1K.
  • New Covenant Trust Company first reported a position in Denali Therapeutics in Q1 2024 and held it in 1 quarter.
  • New Covenant Trust Company's Denali Therapeutics position peaked at $16.1K in Q1 2024.
  • 203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2024.

Based on New Covenant Trust Company's 13F filing for Q2 2024, filed 30 Jul 2024.